Isatuximab plus carfilzomib and dexamethasone led to a higher MRD negativity rate and more complete responses (CR) than carfilzomib and dexamethasone in patients with relapsed/refractory (R/R) multiple myeloma (MM), according to a recent study. Thomas Martin, MD, of the University of California, San Francisco, and colleagues conducted the study, which was a subanalysis of the randomized, open label, multicenter, phase III IKEMA study. Investigators published the results in Blood Advances. ...
Multiple Myeloma
Learn about the newest therapies, interventions, and clinical research on multiple myeloma (MM). Cancer Nursing Today provides the latest clinical data and insights on screening for early detection, COVID-19 vaccine responses in patients with MM, and more. From treatment developments for relapsed/refractory MM and imaging techniques to the latest in CAR T-cell therapy, explore the latest outcomes in MM.
Advertisement
Latest News
This marks the first time a study identified epidemiological and clinical characteristics of SMM in a general population.
Researchers evaluated real-world data on DVd for treatment of patients with relapsed or refractory multiple myeloma.
Both are malignancies associated with significant immunoparesis.
Fabio Efficace, PhD, and a team of researchers investigated IMWG frailty scoring in patients with previously treated disease.
Researchers explored whether screening for MGUS could increase the frequency of patients with MM being diagnosed.
This is according to findings from a phase III study presented during the 2021 ASH Annual Meeting.
Advertisement
Conference Highlights
Advertisement
Advertisement
Popular Stories
Many studies are examining COVID-19's impact on particular subgroups of patients with cancer.
The new data is being used to develop a biomarker tool to predict the efficacy of neoadjuvant pembrolizumab.
Oncology nurses experience stress from many different directions—time pressures, nursing shortages, complex cancer ...
